)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
DexTech Medical
DexTech Medical (DEX) investor relations material
DexTech Medical Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary29 Oct, 2026
Executive summary
October CSR for the OsteoDex Phase I/IIa multiple myeloma study confirmed primary and secondary endpoints: no serious related adverse events and stable disease in all patients during treatment.
More than 70% of patients maintained stable disease after treatment, in some cases for up to 30 weeks; results support continued development and partner discussions.
Financial highlights
Q1 net sales were MSEK 0.0; operating profit and profit after tax were MSEK -1.5 (-1.3); EPS was SEK -0.08 (-0.07).
Operating expenses were MSEK 1.8 (2.2), including MSEK 0.3 (0.8) capitalized for drug development and patents; cash flow for the period was MSEK -1.0 (-0.6).
Outlook and guidance
Board assessment: current liquidity and unchanged business plan support operations at least through end-2028.
Continued development, including a potential Phase III mCRPC study, is resource-intensive and requires an industrial partner; partnership work is ongoing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from DexTech Medical
- OsteoDex achieved strong safety and efficacy in multiple myeloma; liquidity secured through 2028.DEX
Q4 25/26 - OsteoDex shows strong clinical promise despite ongoing losses and no sales, with cash lasting to 2028.DEXQ3 25/26
- OsteoDex myeloma trial shows promise; cash runway extends to 2028 amid ongoing losses.DEXQ2 25/26
- Clinical study progress and strong cash position support continued operations through 2026.DEXQ1 25/26
- 67% of myeloma study patients achieved stable disease, with operations funded through 2026.DEXQ4 24/25
- Losses narrowed, cash reserves remain strong, and clinical progress for OsteoDex advances.DEXQ4 23/24
- Operating loss persists, but promising clinical results and strong cash position support continued R&D.DEXQ1 24/25
- OsteoDex shows promising clinical results as DexTech advances R&D with funding secured to 2026.DEXQ3 24/25
- Promising myeloma study results and strong cash position support DexTech's long-term outlook.DEXQ2 24/25
Next DexTech Medical earnings date
Q2 26/2724 Feb, 2027
DexTech Medical
Next DexTech Medical earnings date
Q2 26/2724 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
DexTech Medical AB is a Sweden-based medical technology company specializing in the development of diagnostic and therapeutic solutions for oncology. The company focuses on creating proprietary products for the treatment and management of cancer, with an emphasis on prostate cancer and related conditions. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Spotlight Stock Market.